G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)

G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)

Introduction Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurological disorder characterised by a selective degeneration of motor neurons (MNs). Stem cell transplantation is considered as a promising strategy in neurological disorders therapy and the possibility of inducing bone marro...

Full description

Bibliographic Details
Main Authors: Christian Lunetta, Letizia Mazzini, Jessica Mandrioli, Isabella Laura Simone, Giuseppe Marrali, Claudia Caponnetto, Vincenzo La Bella, Corrado Tarella, A Bombaci, M Brunetti, S Cammarosano, A Canosa, C Calvo, M Daviddi, G De Marco, P Cugnasco, M Grassano, B Iazzolino, A Ilardi, C Lauritano, A Lomartire, U Manera, L Solero, MC Torrieri; R Vasta, M Gilestro, VE Muccio; P Omedé, F Gerardi, C Cabona, G Novi, E Bersano, F De Marchi, R Spataro, R. Scimè, A Fasano, N Fini, A Gessani, E D’Errico, A Scarafino
Format: Article
Language:English
Published: BMJ Publishing Group 2020-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/3/e034049.full

Internet

https://bmjopen.bmj.com/content/10/3/e034049.full

Similar Items